• Tiziana Life Sciences will present Phase 2a INFORM-MS results for intranasal foralumab at the Jefferies Healthcare Conference in London on November 18, 2026.
• The trial in non-active secondary progressive multiple sclerosis met both primary endpoints, showing reduced brain immune-cell activation versus placebo with favorable tolerability.
• Fatigue also improved meaningfully in a secondary endpoint; the results were previously reviewed during a November 9, 2026, key opinion leader call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120800OMX_____CNEWS_EN_GNW9876232_en) on November 12, 2026, and is solely responsible for the information contained therein.